[{"id":"24cb3342-f64a-4d84-92c7-8c24d302f1d6","acronym":"AOST1521","url":"https://clinicaltrials.gov/study/NCT02487979","created_at":"2022-02-12T16:58:45.516Z","updated_at":"2024-07-02T16:36:18.375Z","phase":"Phase 2","brief_title":"Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma","source_id_and_acronym":"NCT02487979 - AOST1521","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GPNMB","pipe":" | ","alterations":" GPNMB expression","tags":["GPNMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPNMB expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e glembatumumab vedotin (CDX-011)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 02/16/2016","start_date":" 02/16/2016","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-01-18"},{"id":"5b1b16f7-fde5-4dfd-8c85-4342414842b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02363283","created_at":"2021-01-18T11:14:59.793Z","updated_at":"2024-07-02T16:36:41.777Z","phase":"Phase 2","brief_title":"Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma","source_id_and_acronym":"NCT02363283","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GPNMB","pipe":" | ","alterations":" GPNMB expression","tags":["GPNMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPNMB expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e glembatumumab vedotin (CDX-011)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 09/16/2015","start_date":" 09/16/2015","primary_txt":" Primary completion: 07/02/2018","primary_completion_date":" 07/02/2018","study_txt":" Completion: 07/02/2018","study_completion_date":" 07/02/2018","last_update_posted":"2020-08-21"},{"id":"45da2953-ec63-4f4e-8c4c-0e97f056e7cd","acronym":"METRIC","url":"https://clinicaltrials.gov/study/NCT01997333","created_at":"2021-01-18T09:06:53.594Z","updated_at":"2024-07-02T16:37:02.096Z","phase":"Phase 2","brief_title":"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer","source_id_and_acronym":"NCT01997333 - METRIC","lead_sponsor":"Celldex Therapeutics","biomarkers":" GPNMB","pipe":" | ","alterations":" GPNMB expression","tags":["GPNMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPNMB expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • glembatumumab vedotin (CDX-011)"],"overall_status":"Completed","enrollment":" Enrollment 327","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 11/30/2017","primary_completion_date":" 11/30/2017","study_txt":" Completion: 08/07/2018","study_completion_date":" 08/07/2018","last_update_posted":"2019-03-08"},{"id":"f516291f-7989-467e-b2e1-0dc7139623be","acronym":"","url":"https://clinicaltrials.gov/study/NCT03326258","created_at":"2021-07-05T17:09:17.907Z","updated_at":"2024-07-02T16:37:08.906Z","phase":"Phase 1/2","brief_title":"Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03326258","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GPNMB","pipe":" | ","alterations":" GPNMB expression","tags":["GPNMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPNMB expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • glembatumumab vedotin (CDX-011)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/20/2018","start_date":" 04/20/2018","primary_txt":" Primary completion: 04/20/2018","primary_completion_date":" 04/20/2018","study_txt":" Completion: 04/20/2018","study_completion_date":" 04/20/2018","last_update_posted":"2018-07-18"},{"id":"39f67f63-9c84-486c-8520-ea9890979174","acronym":"","url":"https://clinicaltrials.gov/study/NCT03473691","created_at":"2022-02-12T17:20:11.346Z","updated_at":"2024-07-02T16:37:10.364Z","phase":"Phase 1","brief_title":"Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer","source_id_and_acronym":"NCT03473691","lead_sponsor":"University of Virginia","biomarkers":" GPNMB","pipe":" | ","alterations":" GPNMB expression","tags":["GPNMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPNMB expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • glembatumumab vedotin (CDX-011)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2018","start_date":" 05/01/2018","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2018-06-01"},{"id":"b1ea3548-1357-4919-8863-692b030155e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03067935","created_at":"2022-02-12T17:11:48.013Z","updated_at":"2024-07-02T16:37:10.634Z","phase":"","brief_title":"Individual Patient Expanded Access-Glembatumumab Vedotin","source_id_and_acronym":"NCT03067935","lead_sponsor":"Celldex Therapeutics","biomarkers":" GPNMB","pipe":" | ","alterations":" GPNMB expression • GPNMB overexpression","tags":["GPNMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPNMB expression • GPNMB overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e glembatumumab vedotin (CDX-011)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2018-05-21"},{"id":"5e81197d-f796-4d97-90a7-6720faaebdc4","acronym":"EMERGE","url":"https://clinicaltrials.gov/study/NCT01156753","created_at":"2021-01-18T04:36:22.562Z","updated_at":"2024-07-02T16:37:20.248Z","phase":"Phase 2","brief_title":"A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer","source_id_and_acronym":"NCT01156753 - EMERGE","lead_sponsor":"Celldex Therapeutics","biomarkers":" HER-2 • GPNMB","pipe":" | ","alterations":" GPNMB expression","tags":["HER-2 • GPNMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPNMB expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • glembatumumab vedotin (CDX-011) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 11/01/2012","study_completion_date":" 11/01/2012","last_update_posted":"2017-07-02"}]